Harness the Power of Your Immune System with CAR T-Cell Therapy

CAR T-cell therapy is one of the most promising new areas of cancer treatment. It uses your body's own white blood cells, called T cells, to recognize and destroy certain cancers. This revolutionary immunotherapy is FDA approved for people with relapsed or refractory B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia in people up to 25 years of age who have previously failed two or more lines of systemic treatment. CAR T has been shown to improve complete remission rates from approximately 10 percent* to up to 55 percent**.

The Mayo Clinic CAR T-Cell Therapy Program is one of a few such landmark programs in the country, and Mayo Clinic was one of a few centers nationwide that treated people as a part of the clinical trial that led to the therapy's FDA approval in 2017.

Choose Mayo Clinic and receive comprehensive care from a multidisciplinary team of experts who are trained and certified to manage CAR T-cell therapy. Mayo Clinic's campus in Florida is nationally recognized for cancer care by U.S. News & World Report and a National Cancer Institute Specialized Program of Research Excellence for lymphoma.

 

Your Safe Destination for Face-to-Face Care
Nothing is more important than your health and that of your family. We've taken steps to make Mayo Clinic in Florida a safe place for patients to receive care from staff in the COVID-19 environment.

For many patients, access to direct care within Mayo Clinic's safe environment is in your best interest. We have also expanded your options for receiving care. Virtual appointments are now available when appropriate.

*Prior to CAR T-cell therapy, the best complete remission rate offered by conventional therapy was less than 10 percent (Crump M, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808).

**With CAR T-cell therapy (axicabtagene ciloleucel) the complete remission rate improved to 50-55 percent (Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017 Dec 28;377(26):2531-2544.)

get care now

Or call 904-990-5980. M-F 8 a.m.-5 p.m. Eastern